Scholarlink

<p>Liver fibrosis, a critical pathological consequence of chronic liver injury, remains a therapeutic challenge due to its complex mechanisms and limited effectiveness of conventional treatments. Recent advancements in two-dimensional (2D) nanomaterials, such as graphene derivatives, transition metal dichalcogenides (TMDs), black phosphorus nanosheets (BPNSs), MXenes, and layered double hydroxides (LDHs), have created novel opportunities for antifibrotic therapy. These materials exhibit exceptional physicochemical properties, including ultrahigh surface area, tunable surface chemistry, biocompatibility, and photothermal/electrochemical functionalities, enabling multifaceted interventions in fibrosis progression. The core therapeutic strategies mainly involve modulating hepatic stellate cells (HSCs) activation, inhibiting excessive extracellular matrix (ECM) deposition, and alleviating oxidative stress and inflammatory responses. However, 2D nanomaterials still face great challenges, such as long-term biosafety, precise functionalization for tissue-specific targeting, and scalable synthetic methods. This review systematically summarizes the recent breakthroughs in antifibrosis strategies based on 2D nanomaterials, elucidates their potential mechanisms of action, and explores the prospects for clinical translation of these nanoplatforms. Serving as a nexus between materials science and hepatology, 2D nanomaterials offer revolutionary prospects for precision medicine applications in hepatic fibrosis management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recent advances in two-dimensional nanomaterials for the treatment of liver fibrosis

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Yuan Yang,
  • Tao Guo,
  • Ya-Qi Zhu,
  • Hao Sun,
  • Bin Zeng,
  • Xuan Yi,
  • Ming-Xuan Liu

摘要

Liver fibrosis, a critical pathological consequence of chronic liver injury, remains a therapeutic challenge due to its complex mechanisms and limited effectiveness of conventional treatments. Recent advancements in two-dimensional (2D) nanomaterials, such as graphene derivatives, transition metal dichalcogenides (TMDs), black phosphorus nanosheets (BPNSs), MXenes, and layered double hydroxides (LDHs), have created novel opportunities for antifibrotic therapy. These materials exhibit exceptional physicochemical properties, including ultrahigh surface area, tunable surface chemistry, biocompatibility, and photothermal/electrochemical functionalities, enabling multifaceted interventions in fibrosis progression. The core therapeutic strategies mainly involve modulating hepatic stellate cells (HSCs) activation, inhibiting excessive extracellular matrix (ECM) deposition, and alleviating oxidative stress and inflammatory responses. However, 2D nanomaterials still face great challenges, such as long-term biosafety, precise functionalization for tissue-specific targeting, and scalable synthetic methods. This review systematically summarizes the recent breakthroughs in antifibrosis strategies based on 2D nanomaterials, elucidates their potential mechanisms of action, and explores the prospects for clinical translation of these nanoplatforms. Serving as a nexus between materials science and hepatology, 2D nanomaterials offer revolutionary prospects for precision medicine applications in hepatic fibrosis management.